Zobrazeno 1 - 10
of 59
pro vyhledávání: ''
Autor:
Kunihiko Kobayashi, Kei Takamura, Koichi Minato, Yukio Hosomi, Akira Inoue, Yuka Fujita, Tatsuro Fukuhara, Toshiyuki Harada, Toshihiro Nukiwa, Koichi Hagiwara, Akihiko Gemma, Satoshi Morita, Shunichi Sugawara, Kazuhisa Takahashi, Terufumi Kato
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 38(2)
PURPOSE Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor combined with cytotoxic chemotherapy is highly effective for the treatment of advanced non–small-cell lung cancer (NSCLC) with EGFR mutations; however, little is known about
Autor:
Yukito Ichinose, Terufumi Kato, Toyoaki Hida, Kaoru Kubota, Fumihiro Oshita, Kiyotaka Yoh, Hidetoshi Hayashi, Hiroshi Tanaka, Chih-Bin Lin, Kazuhiko Nakagawa, Takayuki Asato, James Chih-Hsin Yang, Eun Kyung Cho, Hiroshige Yoshioka, Kaori Hara, Keunchil Park, Hiroyasu Kaneda, Kazuhiko Yamada, Kyung Hee Lee
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 35(32)
Purpose This phase III, randomized, placebo-controlled, double-blind study determined whether motesanib improved progression-free survival (PFS) compared with placebo in combination with paclitaxel and carboplatin (P/C) in East Asian patients with st
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 35(23)
Purpose To evaluate the efficacy of the addition of palifosfamide to carboplatin and etoposide in extensive stage (ES) small-cell lung cancer (SCLC). Patients and Methods MATISSE was a randomized, open-label, adaptive phase III study. Previously untr
Autor:
Siraj M. Ali, Joo Hang Kim, Moon Young Choi, Eun Kyung Cho, Hye Ryun Kim, Sun Min Lim, Jin-Haeng Chung, Myung-Ju Ahn, Jong-Seok Lee, Young Joo Min, Sung Sook Lee, Yun-Gyoo Lee, Bong-Seog Kim, Min Jeong Lee, Yoon-La Choi, Byoung Chul Cho, Hyo Sup Shim, Ki Hyeong Lee, Maria Kim
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 35(23)
Purpose ROS1 rearrangement is a distinct molecular subset of non–small-cell lung cancer (NSCLC). We investigated the efficacy and safety of ceritinib in patients with ROS1-rearranged NSCLC. Patients and Methods We enrolled 32 patients with advanced
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 31(28)
Purpose Hispanics in the United States have lower age-adjusted mortality resulting from non–small-cell lung cancer (NSCLC) compared with non-Hispanic whites (NHWs). The purpose of this study was to evaluate individual, clinical, and neighborhood fa
Autor:
Michael S. Rabin, Craig C. Earle, Mary Beth Landrum, Nancy L. Keating, Elizabeth B. Lamont, Barbara J. McNeil, Samuel R. Bozeman, Steven H. Krasnow, Lawrence N. Shulman, Jennifer R. Brown
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 30(10)
Purpose The Veterans Health Administration (VHA) provides high-quality preventive chronic care and cancer care, but few studies have documented improved patient outcomes that result from this high-quality care. We compared the survival rates of older
Autor:
Thomas J. Fitzgerald, Tien Hoang, David H. Johnson, Joan H. Schiller, Steven A. Belinsky, Minesh P. Mehta, Suzanne E. Dahlberg
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 30(6)
Purpose The primary objective of this study was to compare the survival of patients with unresectable stage III non–small-cell lung cancer (NSCLC) treated with combined chemoradiotherapy with or without thalidomide. Patients and Methods Patients we
Autor:
Kwok K. Wong, Christine Powell, Keith D. Eaton, Susan Quinn, Benjamin Besse, Revathi Ananthakrishnan, Jean-Charles Soria, Amy Freyman, Thomas J. Lynch, Barbara J. Gitlitz, Vincent A. Miller, Charles Zacharchuk, Lecia V. Sequist
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 28(18)
Purpose Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have had a significant impact on non–small-cell lung cancer (NSCLC) outcomes, particularly for patients with EGFR mutations. Resistance emerges after 9 to 12 months,
Autor:
Paul A. Bunn, Wilbur A. Franklin, Joe B. Putnam, David R. Gandara, Eric Vallières, Kari Chansky, John Crowley, Robert J. Ginsberg, Katherine M.W. Pisters
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 28(11)
Purpose Patients with early-stage non–small-cell lung cancer (NSCLC) have a poor prognosis even after complete resection. Earlier studies of preoperative (induction) chemotherapy in resectable NSCLC demonstrated feasibility and encouraging survival
Autor:
Maria Csollak, Filippo de Marinis, Giorgio V. Scagliotti, José Rodrigues Pereira, Beatrix Bálint, Martin Reck, Sandra DiMatteo, Francesco Grossi, Alan Keller, Silvia Novello, Nasser H. Hanna, I. Albert, Maciej Krzakowski, Joachim von Pawel, Osvaldo Rudy Aren, Frank Cihon, Carlos H. Barrios, Michael Thomas, Lisa Cupit, Jose Elias Abrao Miziara
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 28(11)
Purpose This phase III, multicenter, randomized, placebo-controlled trial assessed the efficacy and safety of sorafenib, an oral multikinase inhibitor, in combination with carboplatin and paclitaxel in chemotherapy-naïve patients with unresectable s